These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23218948)

  • 1. Effects of cyclodextrin in two patients with Niemann-Pick Type C disease.
    Matsuo M; Togawa M; Hirabaru K; Mochinaga S; Narita A; Adachi M; Egashira M; Irie T; Ohno K
    Mol Genet Metab; 2013 Jan; 108(1):76-81. PubMed ID: 23218948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intracerebroventricular administration of 2-hydroxypropyl-β-cyclodextrin in a patient with Niemann-Pick Type C disease.
    Matsuo M; Shraishi K; Wada K; Ishitsuka Y; Doi H; Maeda M; Mizoguchi T; Eto J; Mochinaga S; Arima H; Irie T
    Mol Genet Metab Rep; 2014; 1():391-400. PubMed ID: 27896112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of miglustat in Niemann-Pick C disease: a single centre experience.
    Ginocchio VM; D'Amico A; Bertini E; Ceravolo F; Dardis A; Verrigni D; Bembi B; Dionisi-Vici C; Deodato F
    Mol Genet Metab; 2013 Nov; 110(3):329-35. PubMed ID: 23973268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1.
    Maarup TJ; Chen AH; Porter FD; Farhat NY; Ory DS; Sidhu R; Jiang X; Dickson PI
    Mol Genet Metab; 2015; 116(1-2):75-9. PubMed ID: 26189084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.
    Pérez-Poyato MS; Gordo MM; Marfa MP
    Gene; 2012 Sep; 506(1):207-10. PubMed ID: 22750297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adult onset Niemann-Pick type C disease and psychosis: literature review].
    Maubert A; Hanon C; Metton JP
    Encephale; 2013 Oct; 39(5):315-9. PubMed ID: 23928063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C.
    Yasmin N; Ishitsuka Y; Fukaura M; Yamada Y; Nakahara S; Ishii A; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Okada Y; Nishikawa J; Ichikawa A; Iohara D; Hirayama F; Higaki K; Ohno K; Matsuo M; Irie T
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease.
    Tanaka Y; Yamada Y; Ishitsuka Y; Matsuo M; Shiraishi K; Wada K; Uchio Y; Kondo Y; Takeo T; Nakagata N; Higashi T; Motoyama K; Arima H; Mochinaga S; Higaki K; Ohno K; Irie T
    Biol Pharm Bull; 2015; 38(6):844-51. PubMed ID: 26027824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease.
    Tamura A; Yui N
    J Control Release; 2018 Jan; 269():148-158. PubMed ID: 29138063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
    Ory DS; Ottinger EA; Farhat NY; King KA; Jiang X; Weissfeld L; Berry-Kravis E; Davidson CD; Bianconi S; Keener LA; Rao R; Soldatos A; Sidhu R; Walters KA; Xu X; Thurm A; Solomon B; Pavan WJ; Machielse BN; Kao M; Silber SA; McKew JC; Brewer CC; Vite CH; Walkley SU; Austin CP; Porter FD
    Lancet; 2017 Oct; 390(10104):1758-1768. PubMed ID: 28803710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of intrathecal cyclodextrin in patients with Niemann-Pick disease type C.
    Matsuo M; Sakakibara T; Sakiyama Y; So T; Kosuga M; Kakiuchi T; Ichinose F; Nakamura T; Ishitsuka Y; Irie T
    Brain Dev; 2024 May; 46(5):207-212. PubMed ID: 38448301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin.
    Berry-Kravis E; Chin J; Hoffmann A; Winston A; Stoner R; LaGorio L; Friedmann K; Hernandez M; Ory DS; Porter FD; O'Keefe JA
    Pediatr Neurol; 2018 Mar; 80():24-34. PubMed ID: 29429782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPGCD outperforms HPBCD as a potential treatment for Niemann-Pick disease type C during disease modeling with iPS cells.
    Soga M; Ishitsuka Y; Hamasaki M; Yoneda K; Furuya H; Matsuo M; Ihn H; Fusaki N; Nakamura K; Nakagata N; Endo F; Irie T; Era T
    Stem Cells; 2015 Apr; 33(4):1075-88. PubMed ID: 25522247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of 2-hydroxyalkylated β-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease.
    Kondo Y; Tokumaru H; Ishitsuka Y; Matsumoto T; Taguchi M; Motoyama K; Higashi T; Arima H; Matsuo M; Higaki K; Ohno K; Irie T
    Mol Genet Metab; 2016 Jul; 118(3):214-219. PubMed ID: 27184436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.
    Yamada Y; Ishitsuka Y; Kondo Y; Nakahara S; Nishiyama A; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kamei S; Shuto T; Kai H; Hayashino Y; Sugita M; Kikuchi T; Hirata F; Miwa T; Takeda H; Orita Y; Seki T; Ohta T; Kurauchi Y; Katsuki H; Matsuo M; Higaki K; Ohno K; Matsumoto S; Era T; Irie T
    Br J Pharmacol; 2021 Jul; 178(13):2727-2746. PubMed ID: 33782944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series.
    Pineda M; Perez-Poyato MS; O'Callaghan M; Vilaseca MA; Pocovi M; Domingo R; Portal LR; Pérez AV; Temudo T; Gaspar A; Peñas JJ; Roldán S; Fumero LM; de la Barca OB; Silva MT; Macías-Vidal J; Coll MJ
    Mol Genet Metab; 2010 Apr; 99(4):358-66. PubMed ID: 20056559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease.
    Vite CH; Bagel JH; Swain GP; Prociuk M; Sikora TU; Stein VM; O'Donnell P; Ruane T; Ward S; Crooks A; Li S; Mauldin E; Stellar S; De Meulder M; Kao ML; Ory DS; Davidson C; Vanier MT; Walkley SU
    Sci Transl Med; 2015 Feb; 7(276):276ra26. PubMed ID: 25717099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1.
    Yergey AL; Blank PS; Cologna SM; Backlund PS; Porter FD; Darling AJ
    PLoS One; 2017; 12(4):e0175478. PubMed ID: 28414792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study.
    Patterson MC; Vecchio D; Prady H; Abel L; Wraith JE
    Lancet Neurol; 2007 Sep; 6(9):765-72. PubMed ID: 17689147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracerebroventricular 2-hydroxypropyl-γ-cyclodextrin alleviates hepatic manifestations without distributing to the liver in a murine model of Niemann-Pick disease type C.
    Yamada Y; Ishitsuka Y; Fukaura-Nishizawa M; Kawata T; Ishii A; Shirakawa A; Sakai T; Tanaka M; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Seki T; Kurauchi Y; Katsuki H; Higaki K; Ikeda R; Matsuo M; Era T; Irie T
    Life Sci; 2024 Aug; 350():122776. PubMed ID: 38852794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.